Top 5 Indian Generic Medicine Suppliers in Latin America
Generic Medicine

Top 5 Indian Generic Medicine Suppliers in Latin America

112 Views

The demand for generic Medicine / Drugs is increasing in Latin America, and Indian pharmaceutical companies realize this opportunity’s great potential. Efficient and affordable medicines are always required, making this a flourishing market for drugmakers.

The worldwide generic drugs market is forecasted to increase at a compound annual growth rate (CAGR) of 8.7%, meaning that, in the projection period 2016 to 2021, the worldwide market will rise from almost $352 billion to $533 billion.

In this article, the top five Indian generic pharmaceuticals suppliers, manufacturers and distributors are listed:

JoinHub Pharma

JoinHub Pharma is an award-winning Pharmaceutical Company in India. We hold a reputed name with regards to branded medicines and generic medicines. Our company is certified by the highest authority like WHO, FDA, ISO 9001:2008, GMP, etc. We are a top generic pharma manufacturer, supplier, and distributor in Latin America and are known for our top-of-the-line quality pharma products and services. Without a doubt, we are considered to be one of the best generic pharmaceutical companies in India.

In fact, 85% of our revenue is generated by way of exporting to MIDDLE EAST, CIS, and AFRICA production facilities. We are famous for our widest list of medicines which contains more than 1000+ pharma products.

Based in India, JoinHub Pharma is a generic pharma company in India with a broad footprint covering the US, Europe, South-East Asia, Middle East, and South Africa. It manufactures more than 200 generic drugs and complex APIs in a wide range of therapeutic areas, including cardiovascular, diabetes, HIV, oncology, infectious diseases, hepatitis, ophthalmology, urology, neurosciences, respiratory, and women’s health.

Dr. Reddy

The global generics segment of Dr. Reddy’s accounted for approximately 80% of the company’s revenue in 2018, with North America being the biggest contributor.

As of March 2018, the company filed 20 abbreviated new drug applications (ANDAs) and had 110 generic filings pending approval with the US FDA. Moreover, it launched five first-generic-to-launch (FGTL) products in Brazil.

Based in India, Dr. Reddy’s is an Indian pharmaceutical company whose generic formulations business offers more than 200 high-quality generic medicines worldwide, with over 20 assets falling under the complex generics category, including decitabine, fondaparinux, and azacitidine injections.

The company’s generic formulations segment includes tablets, capsules, injectables, and topical creams. Nise (Nimesulide), Stamlo (Amlodipine Besylate), Omez (Omeprazole), and Razo (Rabeprazole) are a couple of its products available in Latin America’s emerging markets.

Teva Pharmaceutical

Teva Pharmaceuticals’ 2018 revenues in North America decreased by 22% as compared to 2017 because of the price erosion and volume reductions. They have launched generic versions of medicines such as Solodyn®, Aloxi®, Syprine®, Estrace®, Lialda®, Uceris®, and Elidel® in the region in 2018.

The company’s European revenues increased by 4% to $3.6bn, compared to 2017. The revenue growth resulted from an increase in OTC medicine sales and the launch of new pharma products, which offset the impact of price cuts of generics in the first half of 2018. However, the overall revenue was affected marginally in the second half of 2018 because of the dismissal of Teva’s joint venture with PGT Healthcare.

Teva Pharmaceuticals offers diverse products in various segments such as specialty, generic, OTC, and APIs.

Cipla

Cipla’s revenues progressed marginally compared to the earlier year, with the generics business in Latin America contributing around 21% to the domestic business revenues as of March 2018.

The company was ranked as one of the top ten generic Pharma manufacturers in the US, with 13 out of 52 products ranked as number one, according to IQVIA IMS RQTR as of March 2018.

Cipla is working to develop complex generic formulations based on nanotechnology for the US market.

Lupin

Lupin’s generics business held 90% of the company’s total revenues in the US in 2018. It was established in 1968, and while its primary focus is generic drugs, it additionally produces branded medicines and API (active pharmaceutical ingredients).

Lupin filed 20 generic products in many geographic regions worldwide, which includes the APAC (Japan & Australia), Canada, EMEA (Europe, Middle East, and Africa), and Latin America (Brazil & Mexico), and got 22 approvals in 2018.

Lupin also got 24 ANDA approvals out of 36 ANDA files in the US in 2018.

Lupin is a pharma company based in India with many segments, including generic products, biotechnology products, complex generics, APIs, and specialty.

If you’re looking for generic medicines at an affordable rate, contact JoinHub Pharma – a leading generic pharma company in India.

Simply drop them an email at [email protected] or call directly on +91 97247 25604.

 

You may also like to read these blogs:-

Leave a comment

CALL ME BACK